Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.37 |
| ▸ | NAMPT | P43490 | 9/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131144 | 0.92 | NAMPT (0.37) | P2RX7NAMPTPTGS2EPHX2KMT2A | |
| SCHEMBL4125823 | 0.92 | NAMPT (0.38) | P2RX7NAMPTPTGS2EPHX2 | |
| SCHEMBL4135640 | 0.91 | NAMPT (0.37) | P2RX7NAMPTPTGS2EPHX2 | |
| SCHEMBL4130432 | 0.91 | NAMPT (0.39) | NAMPTPTGS2EPHX2 | |
| SCHEMBL4119630 | 0.90 | RIPK1 (0.38) | P2RX7NAMPTPTGS2EPHX2KMT2A | |
| SCHEMBL4135433 | 0.89 | NAMPT (0.37) | NAMPT | |
| SCHEMBL4136915 | 0.88 | NAMPT (0.37) | NAMPTPTGS2EPHX2 | |
| SCHEMBL4135868 | 0.88 | NAMPT (0.39) | NAMPTPTGS2EPHX2KMT2A | |
| SCHEMBL4131518 | 0.87 | SCN9A (0.37) | P2RX7NAMPTPTGS2EPHX2KMT2A | |
| SCHEMBL4129210 | 0.85 | P2RX7 (0.37) | P2RX7NAMPTPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| EP-2190822-A2 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009041705-A9 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2009-08-13 | — | — | WO | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2009041705-A2 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | P2RX7 1303/4885NAMPT 2129/4885PTGS2 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.